Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc.
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Vaxcyte Announces Pricing of $550 Million Public Offering
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
SG Americas Securities LLC Buys 14,421 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Brokerages
Vaxcyte's Chief Technical Ops Officer Sells Shares
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 9,743 Shares
Vaxcyte (NASDAQ:PCVX) SVP Elvia Cowan Sells 11,623 Shares
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of “Moderate Buy” from Analysts
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte: Financial Durability And The Case For Disruption
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Edgestream Partners L.P. Takes $1.61 Million Position in Vaxcyte, Inc. $PCVX
8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP
Bank of Montreal Can Buys 1,274 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte (PCVX) Q2 Loss Widens 11%
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript